AgeX Therapeutics (NYSE:AGE) Trading Down 11.9%

AgeX Therapeutics, Inc. (NYSE:AGE)’s stock price fell 11.9% during mid-day trading on Monday . The company traded as low as $11.10 and last traded at $11.10. 3,700 shares were traded during mid-day trading, a decline of 4% from the average session volume of 3,849 shares. The stock had previously closed at $12.60.

AgeX Therapeutics Trading Down 11.9 %

The stock has a market cap of $11.99 million, a P/E ratio of -0.85 and a beta of 1.18. The firm’s fifty day moving average is $3.67 and its 200 day moving average is $1.49.

Institutional Trading of AgeX Therapeutics

An institutional investor recently raised its position in AgeX Therapeutics stock. Sigma Planning Corp grew its stake in AgeX Therapeutics, Inc. (NYSE:AGE) by 29.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 181,385 shares of the company’s stock after purchasing an additional 41,685 shares during the period. Sigma Planning Corp owned about 0.48% of AgeX Therapeutics worth $123,000 as of its most recent SEC filing. Institutional investors own 12.50% of the company’s stock.

About AgeX Therapeutics

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.